ArticleTargeted oncology2026

Association of TP53 Truncating Mutations with Time to Treatment Failure after First-Line Chemoimmunotherapy in HER2-Mutant Non-Small Cell Lung Cancer.

Akihiro Yoshimura et al.PubMed ↗Publisher ↗

No numbers read from the abstract.